Results 11 to 20 of about 4,918,610 (234)

Direct factor Xa inhibitor in the prevention of thromboembolism [PDF]

Health Problems of Civilization, 2019
Venous thromboembolism is the third most common cause of vascular death after myocardial infarction and stroke, and is associated with considerable morbidity and premature mortality. The incidence of the most serious consequence of venous thromboembolism,
Viktor Meretskyi, Iryna Meretska, Vasyl Pertsovych   +2 more
doaj   +2 more sources

Gla-domainless factor Xa: molecular bait to bypass a blocked tenase complex [PDF]

Haematologica, 2012
Background Hemophilia is caused by deficiencies in coagulation factor VIII or IX, resulting in direct blockade of the intrinsic tenase complex and indirect blockade of the extrinsic tenase complex which is rapidly inhibited upon binding of factor Xa to ...
Raphaël Marlu, Benoît Polack
doaj   +2 more sources

Non-contrast CT Markers of Hematoma Expansion and Andexanet Response in Factor Xa Inhibitor-Associated Intracerebral Hemorrhage: An Analysis from ANNEXa-I Trial. [PDF]

Ann Neurol
In this post hoc analysis of the ANNEXa‐I trial (n = 434), we evaluated non‐contrast computed tomography (NCCT) markers of hematoma expansion (HE) in factor Xa inhibitor (FXai) –associated intracerebral hemorrhage (ICH). At least one NCCT marker was present in 72.1%, and HE (≥12.5 mL or ≥ 35% increase in hematoma volume) occurred in 31.8 ...
Tanaka K, Pensato U, Alshamrani M, Katsanos AH, Balali P, Ray S, Kasner SE, Beyer-Westendorf J, Toni D, Seiffge DJ, Molina C, Tanne D, Członkowska A, Lindgren AG, Bereczki D, Sandset EC, Tsivgoulis G, Christensen H, Coutinho JM, Verhamme P, Amarenco P, Lemmens R, Veltkamp R, Middeldorp S, Robinson T, Milling TJ, Lang W, Tedium-Cruz V, Crowther M, Xu L, Knutsson M, Ladenvall P, Eikelboom JW, Sharma M, Shoamanesh A, Demchuk AM.   +35 more
europepmc   +2 more sources

Anticoagulation by factor Xa inhibitors [PDF]

Journal of Thrombosis and Haemostasis, 2010
Therapeutic agents that regulate blood coagulation are critical to the management of thrombotic disorders, with the selective targeting of factor (F) Xa emerging as a promising approach.To assess anticoagulant strategies targeting FXa.A deterministic computational model of tissue factor (Tf)-initiated thrombin generation and two empirical experimental ...
T, Orfeo, S, Butenas, K E, Brummel-Ziedins, M, Gissel, K G, Mann   +4 more
openaire   +2 more sources

Edoxaban: an update on the new oral direct factor Xa inhibitor. [PDF]

, 2014
Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in a concentration-dependent manner. This review describes the extensive clinical development program of edoxaban, including phase III studies in patients with ...
Camm, AJ, Bounameaux, H, A. John Camm, Henri Bounameaux, Camm AJ, Bounameaux H   +5 more
core   +1 more source

Evolutionary dynamics on a regular networked structured and unstructured multi‐population

International Journal of Robust and Nonlinear Control, EarlyView., 2023
Abstract In this paper, we study collective decision‐making in a multi‐population framework, where groups of individuals represent whole populations that interact by means of a regular network. Each group consists of a number of players and every player can choose between two options.
Wouter Baar, Leonardo Stella, Dario Bauso   +2 more
wiley   +1 more source

Synthesis, Docking, and In Vitro Anticoagulant Activity Assay of Hybrid Derivatives of Pyrrolo[3,2,1-ij]Quinolin-2(1H)-one as New Inhibitors of Factor Xa and Factor XIa

Molecules, 2020
Coagulation factor Xa and factor XIa are proven to be convenient and crucial protein targets for treatment for thrombotic disorders and thereby their inhibitors can serve as effective anticoagulant drugs.
Nadezhda Novichikhina, Ivan Ilin, Anna Tashchilova, Alexey Sulimov, Danil Kutov, Irina Ledenyova, Mikhail Krysin, Khidmet Shikhaliev, Anna Gantseva, Ekaterina Gantseva, Nadezhda Podoplelova, Vladimir Sulimov   +11 more
doaj   +1 more source

Intracranial hemorrhage in patient treated with rivaroxaban

Hematology Reports, 2014
Rivaroxaban is an oral factor Xa inhibitor used for stroke prevention in atrial fibrillation. There are currently no evidence-based guidelines for the treatment of hemorrhagic side effects of factor Xa inhibitors.
Michelle Molina, Virany H. Hillard, Robert Fekete   +2 more
doaj   +1 more source

Vasorelaxing Action of the Kynurenine Metabolite, Xanthurenic Acid: The Missing Link in Endotoxin-Induced Hypotension?

Frontiers in Pharmacology, 2017
The kynurenine pathway of tryptophan metabolism is activated by pro-inflammatory cytokines. L-kynurenine, an upstream metabolite of the pathway, acts as a putative endothelium-derived relaxing factor, and has been hypothesized to play a causative role in
Carmine Vecchione, Carmine Vecchione, Francesco Fazio, Albino Carrizzo, Luana Lionetto, Antonio Damato, Luca Capocci, Mariateresa Ambrosio, Giuseppe Battaglia, Valeria Bruno, Valeria Bruno, Michele Madonna, Maurizio Simmaco, Ferdinando Nicoletti, Ferdinando Nicoletti   +14 more
doaj   +1 more source

Inhibitor discovery against blood coagulation factor Xa and Bacillus anthracis protective antigen.

, 2009
Inhibitor discovery against blood coagulation factor Xa and Bacillus anthracis protective ...
Oukseub. Lee (7966415)
core   +3 more sources